Cargando…
Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer
Immunotherapy has changed the treatment strategy of non-small cell lung cancer (NSCLC) in recent years, among which anti-PD-1/PD-L1 antibodies are the most used. However, the majority of patients with NSCLC do not derive benefit from immune checkpoint inhibitors (ICIs). Vascular abnormalities are a...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618022/ https://www.ncbi.nlm.nih.gov/pubmed/37915579 http://dx.doi.org/10.3389/fimmu.2023.1265865 |
_version_ | 1785129690863763456 |
---|---|
author | He, Danming Wang, Lu Xu, Jiachen Zhao, Jie Bai, Hua Wang, Jie |
author_facet | He, Danming Wang, Lu Xu, Jiachen Zhao, Jie Bai, Hua Wang, Jie |
author_sort | He, Danming |
collection | PubMed |
description | Immunotherapy has changed the treatment strategy of non-small cell lung cancer (NSCLC) in recent years, among which anti-PD-1/PD-L1 antibodies are the most used. However, the majority of patients with NSCLC do not derive benefit from immune checkpoint inhibitors (ICIs). Vascular abnormalities are a hallmark of most solid tumors and facilitate immune evasion. Thus, combining antiangiogenic therapies might increase the effectiveness of anti-PD-1/PD-L1 antibodies. In this paper, the mechanisms of anti-angiogenic agents combined with anti-PD-1/PD-L1 antibodies are illustrated, moreover, relevant clinical studies and predictive immunotherapeutic biomarkers are summarized and analyzed, in order to provide more treatment options for NSCLC patients. |
format | Online Article Text |
id | pubmed-10618022 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106180222023-11-01 Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer He, Danming Wang, Lu Xu, Jiachen Zhao, Jie Bai, Hua Wang, Jie Front Immunol Immunology Immunotherapy has changed the treatment strategy of non-small cell lung cancer (NSCLC) in recent years, among which anti-PD-1/PD-L1 antibodies are the most used. However, the majority of patients with NSCLC do not derive benefit from immune checkpoint inhibitors (ICIs). Vascular abnormalities are a hallmark of most solid tumors and facilitate immune evasion. Thus, combining antiangiogenic therapies might increase the effectiveness of anti-PD-1/PD-L1 antibodies. In this paper, the mechanisms of anti-angiogenic agents combined with anti-PD-1/PD-L1 antibodies are illustrated, moreover, relevant clinical studies and predictive immunotherapeutic biomarkers are summarized and analyzed, in order to provide more treatment options for NSCLC patients. Frontiers Media S.A. 2023-10-16 /pmc/articles/PMC10618022/ /pubmed/37915579 http://dx.doi.org/10.3389/fimmu.2023.1265865 Text en Copyright © 2023 He, Wang, Xu, Zhao, Bai and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology He, Danming Wang, Lu Xu, Jiachen Zhao, Jie Bai, Hua Wang, Jie Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer |
title | Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer |
title_full | Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer |
title_fullStr | Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer |
title_full_unstemmed | Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer |
title_short | Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer |
title_sort | research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618022/ https://www.ncbi.nlm.nih.gov/pubmed/37915579 http://dx.doi.org/10.3389/fimmu.2023.1265865 |
work_keys_str_mv | AT hedanming researchadvancesinmechanismofantiangiogenictherapycombinedwithimmunecheckpointinhibitorsfortreatmentofnonsmallcelllungcancer AT wanglu researchadvancesinmechanismofantiangiogenictherapycombinedwithimmunecheckpointinhibitorsfortreatmentofnonsmallcelllungcancer AT xujiachen researchadvancesinmechanismofantiangiogenictherapycombinedwithimmunecheckpointinhibitorsfortreatmentofnonsmallcelllungcancer AT zhaojie researchadvancesinmechanismofantiangiogenictherapycombinedwithimmunecheckpointinhibitorsfortreatmentofnonsmallcelllungcancer AT baihua researchadvancesinmechanismofantiangiogenictherapycombinedwithimmunecheckpointinhibitorsfortreatmentofnonsmallcelllungcancer AT wangjie researchadvancesinmechanismofantiangiogenictherapycombinedwithimmunecheckpointinhibitorsfortreatmentofnonsmallcelllungcancer |